Wire · operational-macro
Iambic Therapeutics, AI-Driven Drug Discovery Platform, Files for Nasdaq Global Select Market IPO
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Iambic Therapeutics, an AI-driven biopharma company, filed for an IPO on Nasdaq to fund clinical development of its lead oncology drug candidates, including a brain-penetrant HER2 inhibitor progressing to registrational trials by 2027. The platform integrates proprietary AI models and automated labs to accelerate drug discovery, supported by partnerships with major pharma and tech firms.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
The Nasdaq IPO for Iambic opens a door for AI-driven drug discovery startups to attract public funding competing with legacy biotechs. You must sharpen your platform's clinical progress and pharma tie-ups now to stand out and gain access to capital markets.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics